anti-CD19-CAR
/ Kecellitics Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 01, 2022
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
(clinicaltrials.gov)
- P1 | N=100 | Not yet recruiting | Sponsor: Kecellitics Biotech Company Ltd | Trial completion date: Aug 2022 ➔ Aug 2024 | Trial primary completion date: Aug 2021 ➔ Aug 2023
CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Leukemia • Oncology • CD19
April 05, 2022
Anti-CD19 CAR T as a feasible therapy for refractory/relapsed mixed phenotype acute leukemia patients.
(PubMed, Pediatr Blood Cancer)
- No abstract available
Journal • Hematological Malignancies • Leukemia • Oncology
1 to 2
Of
2
Go to page
1